ERBB2 and adenocarcinoma: In adenocarcinomas (n = 180), KRAS genomic alterations were most frequently observed (32.2%), followed by TP53 (29.4%), PIK3CA (22.2%), STK11 (22.2%), CDKN2A (18.3%), ERBB2 (16.7%), and ARID1A (11.7%) (Figure 2B).